Pre-Op Immunotherapy Combo Makes Headway in Select Gastric Cancers
Plus, novel bispecific antibody tested as first-line therapy for advanced gastric/GEJ cancer
Source: medpagetoday.com
Page 3 - Thierry Andre News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Thierry Andre. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Thierry Andre Today - Breaking & Trending Today
Casablanca Drops Handmade Surfboards for SS21
Surfs Up: Casablanca Drops Bespoke Surfboards and Swimwear: One-of-a-kind boards emblazoned with thematic patterns.
Source: hypebeast.com
Europe approves KEYTRUDA as first-line colorectal cancer therapy
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website. Manage your cookiesI agree Cookie Settings Cookie Settings This website uses cookies to improve your experience whil...
Source: europeanpharmaceuticalreview.com
Merck & Co., Inc.: European Commission Approves KEYTRUDA (pembrolizumab) as First-Line Treatment in Adult Patients With Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer
(2) KEYTRUDA Is First Checkpoint Inhibitor Approved in Europe to Treat MSI-H or dMMR Colorectal Cancer European Approval Based on Results From KEYNOTE-177 Trial Demonstrating KEYTRUDA Significantly Reduced Risk of Disease Progression or Death by 40% Compared With Chemotherapy Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the European Commission has approved KEYTRUDA, Merck's anti-PD-1 therapy, as a monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) ...
Source: finanznachrichten.de
New Anti-PD-1 Drug Active in Advanced Colon Cancer
This article is a collaboration between MedPage Today and: Almost 40% of progressive, advanced gastrointestinal (GI) tumors with mismatch repair deficiency (dMMR) responded to the investigational anti-PD-1 agent dostarlimab, according to a preliminary clinical trial. Overall, 38.7% of 106 patients responded to single-agent treatment with monoclonal antibody, including 36.2% of colorectal cancers (CRC) and 43.2% of all other tumors, which were primarily GI in origin. About three-fourths of patients had some degree of tumor shrinkage. During a median follow-up exceeding 1 year, median duration...
Source: medpagetoday.com